Track argenx SE — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

argenx SE ARGX · Stock Open argenx SE in new tab

960.04 USD
P/E
33.25
EPS
28.87
P/B
178.33
ROE
23.64
Beta
-0.06
Target Price
1147.35 USD
argenx SE logo

argenx SE

🧾 Earnings Recap – Q3 2026

Shares fell 1.8% after earnings, a roughly flat reaction. The quarter showed continued revenue growth, while management emphasized future launches and pipeline milestones rather than offering a new outlook in the provided transcript.

  • Product net sales were $1.7 billion, up 54% year over year and 13% quarter over quarter.
  • U.S. product net sales were $1.5 billion, up 16% quarter over quarter; gross-to-net deductions were 22%, in line with company expectations.
  • Management expects five potential launches in 2027, including pediatric and ocular MG opportunities, an auto-injector, and potential launches across other programs.
  • Argenx expects to file an sBLA for VYVGART in IMNM by year-end and anticipates the EMPASSION Phase III readout in MMN in December.
  • FB102 reported positive Phase II results in celiac disease and is ready to advance into Phase III.
📅
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
P/E33.25
EPS28.87
Book Value5.38
Price to Book178.33
Debt/Equity0.56
% Insiders0.041%
Growth
Revenue Growth0.52%
Earnings Growth0.51%
Estimates
Forward P/E28.82
Forward EPS33.31
Target Mean Price1147.35

DCF valuation

Model fair value for argenx SE (ARGX)
Result
Sign in to run the valuation for ARGX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
23 analysts · consensus Buy · mean target 1147.35 USD (low 861.00, high 1353.00) · as of 14 Nov 2026
Low 861.00
Mean 1147.35
High 1353.00
Price 960.04
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

argenx SE Logo argenx SE Analysis (ARGX)

Netherlands Health Care Official Website Stock

Is argenx SE a good investment? argenx SE (ARGX) is currently trading at 960.04 USD. Market analysts have a consensus price target of 1147.35 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 33.25. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: argenx SE is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is 33.31.

Investor FAQ

Does argenx SE pay a dividend?

No, it does not currently pay a dividend.

What asset class is argenx SE?

argenx SE is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of 28.87.

Company Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Exchange Ticker
NMS (United States) ARGX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion